TY - JOUR
T1 - Novel Agents in Heavily Pretreated Metastatic Gastric Cancer
T2 - More Shadows Than Lights
AU - Roviello, Giandomenico
AU - D'Angelo, Alberto
AU - Roudi, Raheleh
AU - Petrioli, Roberto
AU - Mini, Enrico
PY - 2019/7/4
Y1 - 2019/7/4
N2 - Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
AB - Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
UR - https://www.scopus.com/pages/publications/85069050408
U2 - 10.1155/2019/5692317
DO - 10.1155/2019/5692317
M3 - Review article
C2 - 31354820
SN - 1687-8450
VL - 2019
JO - Journal of oncology
JF - Journal of oncology
M1 - 5692317
ER -
